TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01447225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121
Description: MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: administered at AUC 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: administered IV at 500 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: administered IV at 20 mg/m2 or 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: administered IV at 1000 mg/m2 or 1250 mg/m2
Study: NCT01514123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGX-100
Description: VGX-100 will be administered by IV infusion once every week
Study: NCT04478266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439859
Description: Pharmaceutical form: Tablets Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules/Tablets Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules/Tablets Route of Administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Capsules Route of Administration: Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole-matching placebo
Description: Pharmaceutical form: Capsules Route of Administration: Orally
Study: NCT05065814

Intervention type: OTHER
Group type: OTHER
Intervention: Systemic lupus erythematosus group
Description: Demographic information of systemic lupus erythematosus who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.

Intervention type: OTHER
Group type: OTHER
Intervention: Systemic sclerosis group
Description: Demographic information of Systemic sclerosis who accepted to participate in the study will be obtained, and respiratory and peripheral muscle strength and exercise capacity of the patients will be evaluated with a 6-minute walking test. Patients will be asked to complete the International Physical Activity Questionnaire, the numerical pain questionnaire, the Short Form-36, and the Hospital Anxiety and Depression Questionnaire. In addition, Modified Medical Research Council Dyspnea Scale will be applied by the interviewer.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy control group
Description: Healthy individuals with no chronic diseases who agreed to participate in the study and gave their consent will be included in the study.
Study: NCT02866916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXL01
Description: Treatment will be administered continuously over 24h through the subcutaneous route.
Study: NCT01468675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: risk assessment survey; decision support for providers for prevention based on risk
Study: NCT02317588

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flax Oil
Description: Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
Study: NCT00028782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanidazole
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03734042

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma intrauterine infusion
Description: platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
Study: NCT02918916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
Study: NCT03653975

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03734042

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intrauterine infusion of normal saline at day 11
Study: NCT02399553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer boot intervention
Study: NCT03653975

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02399553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer boot intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer boot intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer boot intervention
Study: NCT04246697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol
Description: Used for both arms, scheduled
Study: NCT01186536

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein supplement
Description: 40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Protein Supplement
Description: 40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement
Description: 40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
Study: NCT00391729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take placebo QD, BID for 4-6 weeks
Study: NCT02699593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens
Study: NCT04246697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Used for both arms, scheduled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Used for both arms PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Used for both arms PRN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Used for both arms PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Used for both arms PRN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Used for Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toradol
Description: Used for Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Used for Arm B - anesthesia block
Study: NCT00097253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to relaxant and stimulant odors
Description: A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to relaxant and stimulant odors
Description: A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to relaxant and stimulant odors
Description: A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
Study: NCT03608670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation using the Extravascular ICD
Description: VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
Study: NCT00904527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation (Schultz)
Description: Patients have relaxation consultations during 2 months
Study: NCT00702429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Analysis of the PNN, analysis of the monocytes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Analysis of the PNN, analysis of the monocytes
Study: NCT02186405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEVOTHYROXINE
Description: administration of levothyroxine
Study: NCT01253499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0037
Description: 75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
Study: NCT01407900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CD-NP
Description: CD-NP as a four hour infusion at 10 ng/kg/min IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose in Water
Description: four hour infusion IV
Study: NCT01884389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
Study: NCT01304394

Intervention type: DRUG
Group type: OTHER
Intervention: Ped3CB
Description: The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
Study: NCT01693965

Intervention type: OTHER
Group type: OTHER
Intervention: sputum samples
Study: NCT00744250

Intervention type: DRUG
Group type: OTHER
Intervention: Pancrelipase
Description: PANCRECARB MS-16
Study: NCT02885051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recording of skin conductance and heart rate variability.
Description: When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
Study: NCT03255772

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography
Description: Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
Study: NCT02205151

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination

Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination
Study: NCT02628691

Intervention type: OTHER
Intervention: Liver fibrosis progression
Description: A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
Study: NCT00913328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast (Singulair)
Description: 10 mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo once daily
Study: NCT04904757

Intervention type: DEVICE
Group type: OTHER
Intervention: Contrast-enhanced spectral mammography (CESM)
Description: CESM is a mammogram performed after the injection of IV contrast. CESM is used most often when additional information is needed after a standard mammogram. CESM has also been used to determine the extent of a known breast cancer, to screen patients at high risk for developing breast cancer due to a family history or positive cancer genes, and for women with dense breast tissue. Two images are taken almost at the same time during the exam, after the iodine based contrast injection is administered. The first image is comparable to a regular mammogram. The second image shows areas that take up the contrast (enhance) showing increased blood flow. Breast cancers often enhance with contrast due to a greater amount of blood vessels. Non-cancerous lesions can also have greater blood flow.
Study: NCT04034758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
Description: heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: Oral administration of 30 placebo capsule containing edible pigmented starch
Study: NCT00580801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a (180 microgram \[mcg\] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
Study: NCT00191269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
Study: NCT00580801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
Study: NCT02664337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment information
Description: Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
Study: NCT01877616

Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test
Description: Polysomnography

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic test
Description: overnight polysomnography
Study: NCT00542386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
Study: NCT03052946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulking agent
Description: Filling bulking agent in the anal canal

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoanal electrostimulation
Description: The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
Study: NCT00614406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: One 400mg tablet daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet daily.
Study: NCT00310401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 5 mg nebulized q4h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: 5 mg nebulized q4h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
Study: NCT00820118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Description: The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~* atazanavir : 300 mg/d~* ritonavir : 100 mg/d~* abacavir 600 mg and lamivudine 300 mg : once a day~* tenofovir 245 mg and emtricitabine 200 mg : once a day
Study: NCT03610750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychiatric medications and evidence-based psychotherapies
Description: Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychiatric medications and evidence-based psychotherapies
Description: Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychiatric medications and evidence-based psychotherapies
Description: Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
Study: NCT02561403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVO multitask video game
Description: Participants will play a multitasking game for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVO words video game
Description: Participants will play a word puzzle game for 4 weeks
Study: NCT00477100

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, and stool

Intervention type: OTHER
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Undergo collection of medical data

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary Studies
Study: NCT01850992

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CPAP
Description: Effective CPAP will be administered

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP
Description: This is placebo CPAP